Canavan Disease
11
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Natural History Study of Patients With Canavan Disease (CANinform Study)
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
The Myelin Disorders Biorepository Project
Early Check: Expanded Screening in Newborns
Canavan-Single Patient IND
A Natural History Study of Canavan Disease
Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent.
Lithium and Acetate for Canavan Disease
Oral Glyceryl Triacetate (GTA) in Newborns With Canavan